JHL Biotech
Develops biosimilars and accelerates the development programs of distinguished clients and partners through the provision of contract development and manufacturing services.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A Valuation: $750m | Late VC | ||
| Total Funding | 000k | ||
| EUR | 2016 | 2017 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
JHL Biotech is a Contract Development and Manufacturing Organization (CDMO) that specializes in the development and production of biologics, including biosimilars. The company operates in the global healthcare market, focusing on increasing the availability of biotechnology medicines. JHL Biotech serves pharmaceutical and biotechnology companies by providing comprehensive services from cell line development to cGMP manufacturing and regulatory affairs. The business model revolves around offering end-to-end solutions for biologics development, which allows clients to bring their products to market efficiently and cost-effectively. Revenue is generated through service contracts and long-term partnerships with clients. The company has a strong presence in Taiwan and China, with facilities designed to meet global regulatory standards. JHL Biotech aims to improve global healthcare by making high-quality biologics more accessible.
Keywords: Biologics, CDMO, Biosimilars, Cell Line Development, cGMP Manufacturing, Regulatory Affairs, Global Healthcare, Biotechnology, Pharmaceutical Services, Market Expansion.